On October 18, 1985, the DEA issued a Notice of Proposed Rulemaking to transfer "Synthetic Dronabinol in Sesame Oil and Encapsulated in Soft Gelatin Capsules" — a pill form of Δ9-tetrahydrocannabinol, the main psychoactive component of cannabis, sold under the brand name Marinol — from Schedule I to Schedule II ("DEA 50 FR 42186-87"). The government issued its final rule rescheduling the drug on July 13, 1986 ("DEA 51 FR 17476-78"). The disparate treatment of cannabis and the expensive, patentable Marinol prompted reformers to question the DEA's consistency.